Free Trial
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

Vivos Therapeutics logo
$0.66 +0.01 (+2.23%)
Closing price 05/27/2026 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+1.35%)
As of 05/27/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Advanced

Key Stats

Today's Range
$0.66
$0.75
50-Day Range
$0.58
$1.47
52-Week Range
$0.55
$7.95
Volume
228,132 shs
Average Volume
156,558 shs
Market Capitalization
$9.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75
Consensus Rating
Hold

Company Overview

Vivos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

VVOS MarketRank™: 

Vivos Therapeutics scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vivos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Vivos Therapeutics has a consensus price target of $2.75, representing about 316.0% upside from its current price of $0.66.

  • Amount of Analyst Coverage

    Vivos Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Vivos Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vivos Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vivos Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    7.19% of the float of Vivos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vivos Therapeutics has a short interest ratio ("days to cover") of 6.44.
  • Change versus previous month

    Short interest in Vivos Therapeutics has recently increased by 36.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vivos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vivos Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Vivos Therapeutics has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Vivos Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for VVOS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    5 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $1,813,858.00 in company stock, which represents 19.7388% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Vivos Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,813,858.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    2.10% of the stock of Vivos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    26.35% of the stock of Vivos Therapeutics is held by institutions.

  • Read more about Vivos Therapeutics' insider trading history.
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VVOS Stock News Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More Headlines

VVOS Stock Analysis - Frequently Asked Questions

Vivos Therapeutics' stock was trading at $2.03 on January 1st, 2026. Since then, VVOS stock has decreased by 67.4% and is now trading at $0.6611.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Wednesday, May, 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.07. The firm earned $5.14 million during the quarter, compared to the consensus estimate of $4.35 million. Vivos Therapeutics had a negative net margin of 127.70% and a negative trailing twelve-month return on equity of 2,325.64%.

Shares of Vivos Therapeutics reverse split before market open on Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Vivos Therapeutics (VVOS) raised $21 million in an initial public offering on Thursday, December 10th 2020. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Vivos Therapeutics' top institutional investors include Sequoia Financial Advisors LLC (0.18%). Insiders that own company stock include Michael C Skaff and Ronald Kirk Huntsman.
View institutional ownership trends
.

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP).

Company Calendar

Last Earnings
5/20/2026
Today
5/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:VVOS
CIK
1716166
Fax
N/A
Employees
160
Year Founded
2013

Price Target and Rating

High Price Target
$3.00
Low Price Target
$2.50
Potential Upside/Downside
+316.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.17 million
Net Margins
-127.70%
Pretax Margin
-128.36%
Return on Equity
-2,325.64%
Return on Assets
-98.12%

Debt

Debt-to-Equity Ratio
3.31
Current Ratio
0.27
Quick Ratio
0.27

Sales & Book Value

Annual Sales
$17.44 million
Price / Sales
0.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.09) per share
Price / Book
-7.35

Miscellaneous

Outstanding Shares
13,900,000
Free Float
13,603,000
Market Cap
$9.19 million
Optionable
Optionable
Beta
6.25

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:VVOS) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners